New combo therapy shows promise for uterine precancer in obese women
NCT ID NCT05172999
First seen Mar 17, 2026 · Last updated May 20, 2026 · Updated 6 times
Summary
This study tested whether a medication (polyethylene glycol loxenatide) combined with a hormone-releasing IUD (LNG-IUS) can better treat atypical endometrial hyperplasia, a precancerous condition of the uterine lining. The 30 participants were women with obesity who wanted to preserve their fertility or keep their uterus. The main goal was to see if the combination led to a complete disappearance of abnormal cells after 32 weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Obstetrics & Gynecology Hospital of Fudan University
Shanghai, Shanghai Municipality, 200090, China
Conditions
Explore the condition pages connected to this study.